All antibody drug conjugate (ADC) articles
-
NewsDaiichi Sankyo picks Dr John Tsai to head up R&D
The ex-Novartis drug development head will lead the pharmaceutical company’s global R&D operations.
-
NewsAstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval
FDA approval of the drug in combination with Perjeta initiates a $150 million milestone payment to Daiichi Sankyo from AstraZeneca under their joint collaboration.
-
ArticleA careful calibration: balancing small molecule needs and biologic innovation
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
-
NewsTakeda expands its ADC and immuno-oncology pipeline as Innovent deal closes
The $11bn collaboration with the Chinese biopharma company gives Takeda the rights to several next-generation candidates.
-
NewsAxplora talks reliability-first investments to secure API supply
The CDMO’s programme, presented at CPHI Frankfurt 2025, combines responsiveness to new demand and operational rigour without jeopardising supply.
-
News
Chinese ADC dominance expected to drive the first bispecific approval
The first bispecific antibody drug conjugate market entrants are predicted to be in China or Japan as East Asia becomes a key battleground for local and multinational players.
-
ArticleM&A outlook for pharma in 2025
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.
-
NewsRoche to advance potentially best-in-class antibody drug conjugate
As part of the collaboration and license agreement, Innovent Biologics, Inc. could receive up to $1 billion, subject to developmental success of the biologic candidate.